Marilyn Tavenner, president and CEO of America’s Health Insurance Plans (AHIP), explains some of the biggest transitions she faced in moving from the public sector of working with HHS to the private sector of now working with AHIP.
Marilyn Tavenner, president and CEO of America’s Health Insurance Plans (AHIP), explains some of the biggest transitions she faced in moving from the public sector of working with HHS to the private sector of now working with AHIP.
Transcript (slightly modified):
What was the biggest transition for you when you moved from the public side with HHS to the private side with AHIP?
I guess I would say there really have been very few challenges because these are a group of individuals that I had gotten to know over the last 5 years. We had worked closely when I was with CMS with insurance plans and their senior leadership and so you move over to AHIP and you’re representing insurance plans, senior leadership and so that part was pretty easy.
I also think that going from government work to the private sector, either way you’re talking about dealing with a corporation of a varying size. So it’s really learning the people and learning the process, so that certainly was a part of the challenge. I would say that deciding strategy for 16 and then being able to execute on strategy was part of what we spent the first year doing, including some pretty significant changes in our bylaws, due structure, as well as developed a long-term strategic vision, or in the process of developing a long-term strategic vision for post presidential election. What AHIP should look like and what plans will look like by 2025 and how the organization can support them.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More